2. Academic Validation
  3. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health

  • Life Sci Alliance. 2022 Aug 5;5(12):e202201517. doi: 10.26508/lsa.202201517.
Natasha de Alwis 1 2,  Natalie K Binder 3 2,  Sally Beard 3 2,  Yeukai Tm Mangwiro 3 2,  Elif Kadife 2 4,  James Sm Cuffe 5,  Emerson Keenan 2 4,  Bianca R Fato 3 2,  Tu'uhevaha J Kaitu'u-Lino 2 6,  Fiona C Brownfoot 2 4,  Sarah A Marshall 7,  Natalie J Hannan 3 2
Affiliations

Affiliations

  • 1 Department of Obstetrics and Gynaecology, Therapeutics Discovery and Vascular Function Group, The University of Melbourne and Mercy Hospital for Women, Heidelberg, Australia natasha.dealwis@unimelb.edu.au.
  • 2 Mercy Perinatal, Heidelberg, Australia.
  • 3 Department of Obstetrics and Gynaecology, Therapeutics Discovery and Vascular Function Group, The University of Melbourne and Mercy Hospital for Women, Heidelberg, Australia.
  • 4 Department of Obstetrics and Gynaecology, Obstetrics Diagnostics and Therapeutics Group, The University of Melbourne and Mercy Hospital for Women, Heidelberg, Australia.
  • 5 School of Biomedical Sciences, The University of Queensland, Brisbane, Australia.
  • 6 Department of Obstetrics and Gynaecology, Diagnostics Discovery and Reverse Translation in Pregnancy Group, The University of Melbourne and Mercy Hospital for Women, Heidelberg, Australia.
  • 7 Department of Obstetrics and Gynaecology, The Ritchie Centre, School of Clinical Sciences, Monash University and The Hudson Institute of Medical Research, Clayton, Australia.
PMID: 36260752 DOI: 10.26508/lsa.202201517
Abstract

Preeclampsia affects ∼2-8% of pregnancies worldwide. It is associated with increased long-term maternal Cardiovascular Disease risk. This study assesses the effect of the vasoconstrictor N(ω)-nitro-L-arginine methyl ester (L-NAME) in modelling preeclampsia in mice, and its long-term effects on maternal cardiovascular health. In this study, we found that L-NAME administration mimicked key characteristics of preeclampsia, including elevated blood pressure, impaired fetal and placental growth, and increased circulating endothelin-1 (vasoconstrictor), soluble fms-like tyrosine kinase-1 (anti-angiogenic factor), and C-reactive protein (inflammatory marker). Post-delivery, mice that received L-NAME in pregnancy recovered, with no discernible changes in measured cardiovascular indices at 1-, 2-, and 4-wk post-delivery, compared with matched controls. At 10-wk post-delivery, arteries collected from the L-NAME mice constricted significantly more to phenylephrine than controls. In addition, these mice had increased kidney Mmp9:Timp1 and heart Tnf mRNA expression, indicating increased inflammation. These findings suggest that though administration of L-NAME in mice certainly models key characteristics of preeclampsia during pregnancy, it does not appear to model the adverse increase in Cardiovascular Disease risk seen in individuals after preeclampsia.

Figures
Products